Ronald N. Marcus

Psychiatry

5 Research Pkwy
Wallingford, CT 06492

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial.

Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial.

Journal: The American journal of psychiatry

Published: February 04, 2026

Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.

Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.

Journal: Schizophrenia research

Published: December 03, 2025

Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.

Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.

Journal: The Journal of clinical psychiatry

Published: April 11, 2025

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.

Journal: The Journal of clinical psychiatry

Published: March 06, 2025

Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia.

Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia.

Journal: The Journal of clinical psychiatry

Published: August 28, 2024

Comorbidities and behavioral issues.

Comorbidities and behavioral issues.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: October 12, 2020

A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression.

A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression.

Journal: Postgraduate medicine

Published: January 26, 2019

A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.

A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.

Journal: Addiction biology

Published: January 14, 2019

Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.

Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.

Journal: International journal of clinical practice

Published: September 09, 2014

Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.

Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.

Journal: BMC research notes

Published: May 06, 2014

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.

Journal: CNS spectrums

Published: March 20, 2014

Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change.

Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change.

Journal: Journal of child and adolescent psychopharmacology

Published: October 22, 2013

Showing 1-12 of 18

Last Updated: 09/26/2026